Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of induction chemotherapy with high-dose methotrexate and cytarabine with or without rituximab and thiotepa, followed by whole-brain radiotherapy versus high-dose chemotherapy with autologous stem cell transplantation in newly diagnosed primary CNS lymphoma
2009-012432-32Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate, cytarabine, rituximab, thiotepa and carmustine in primary central nervous system lymphoma (PCNSL) (5 arms), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Complete remission rate after chemotherapy and 2-year progression-free survival. Started Sep 2009; status: completed.
02
Drugs
methotrexatecytarabinerituximabthiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2009-012432-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012432-32.